Real-world experience of atezolizumab and bevacizumab for treatment of advanced hepatocellular carcinoma in a single tertiary center

被引：0
|
作者：
Raharjo, C. V. [1 ]
Joseph, R. [1 ]
Stratton, E. [1 ]
Levy, M. [1 ,2 ]
Prakoso, E. [1 ,3 ]
机构：
[1] Liverpool Hosp, Dept Gastroenterol, Liverpool, England
[2] Univ New South Wales, Sydney, Australia
[3] Univ Sydney, Sydney, NSW, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
106
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [31] Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications
    Lee, Cha Len
    Freeman, Mark
    Burak, Kelly W.
    Moffat, Gordon T.
    O'Donnell, Conor D. J.
    Ding, Philip Q.
    Lyubetska, Hanna
    Meyers, Brandon M.
    Gordon, Vallerie
    Kosyachkova, Ekaterina
    Bucur, Roxana
    Cheung, Winson Y.
    Knox, Jennifer J.
    Tam, Vincent C.
    CANCERS, 2024, 16 (16)
  • [32] Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
    Xiaoqiang Gao
    Rui Zhao
    Huaxing Ma
    Shi Zuo
    BMC Cancer, 23
  • [33] Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
    Gao, Xiaoqiang
    Zhao, Rui
    Ma, Huaxing
    Zuo, Shi
    BMC CANCER, 2023, 23 (01)
  • [34] ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): REAL-WORLD EXPERIENCE FROM A US COMMUNITY ONCOLOGY NETWORK
    Cosgrove, David
    Tan, Amie
    Hernandez, Sairy
    Mahrus, Sami
    Osterland, Andrew
    Murphy, John
    Loaiza-Bonilla, Arturo
    HEPATOLOGY, 2022, 76 : S1308 - S1309
  • [35] Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis
    Hsu, Yu-Chun
    Lin, Po-Ting
    Teng, Wei
    Hsieh, Yi-Chung
    Chen, Wei-Ting
    Su, Chung-Wei
    Wang, Ching-Ting
    Chai, Pei-Mei
    Lin, Chen-Chun
    Lin, Chun-Yen
    Lin, Shi-Ming
    CANCERS, 2024, 16 (20)
  • [36] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Brown, Timothy J.
    Mamtani, Ronac
    Gimotty, Phyllis A.
    Karasic, Thomas B.
    Yang, Yu-Xiao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2345 - 2354
  • [37] Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort
    Jost-Brinkmann, Fabian
    Demir, Muenevver
    Wree, Alexander
    Luedde, Tom
    Loosen, Sven H.
    Mueller, Tobias
    Tacke, Frank
    Roderburg, Christoph
    Mohr, Raphael
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (11) : 1313 - 1325
  • [38] REAL-WORLD EFFECTIVENESS OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN THE PATIENTS WITH HEPATOCELLULAR CARCINOMA: A MULTIINSTITUTIONAL COHORT IN TAIWAN
    Kuo, Y. C.
    Chang, K. C.
    Chen, H. Y.
    VALUE IN HEALTH, 2022, 25 (12) : S475 - S475
  • [39] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Timothy J. Brown
    Ronac Mamtani
    Phyllis A. Gimotty
    Thomas B. Karasic
    Yu-Xiao Yang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2345 - 2354
  • [40] Potential faesability of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma: a real-world analysis
    Stefanini, Benedetta
    Bucci, Laura
    Santi, Valentina
    Reggidori, Nicola
    Rampoldi, Davide
    Lani, Lorenzo
    Trevisani, Franco
    JOURNAL OF HEPATOLOGY, 2022, 77 : S382 - S383
12345